Drug Coated Balloon, Peripheral Arterial Disease
Conditions
Keywords
LUX-PAD, Passeo-18 Lux Long, Passeo-18
Brief summary
This clinical trial will evaluate the study device, Passeo®-18 Lux® paclitaxel-releasing percutaneous transluminal angioplasty (PTA) balloon catheter for the treatment of new or recurring cholesterol-related blockages in the arteries of the lower leg. The device that is used in this trial has been assessed in several previous studies for safety and effectiveness. The device is already approved for use in Europe. It has a "CE mark," which means it meets the European Union's safety, health and performance standards. This trial is being done to gather additional information on how well the device works and how safe it is when used in everyday medical care with specific attention to the longer lengths of the balloon, as it comes in different sizes.
Interventions
PROCEDUREPercutaneous Transluminal Angioplasty with the use of Passeo-18 Lux DCB
This intervention uses the Passeo-18 Lux paclitaxel-releasing percutaneous transluminal angioplasty (PTA) balloon catheter for the treatment of new or recurring cholesterol-related blockages in the arteries of the lower leg.
Sponsors
KANDO Research
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Study participant is ≥ 18 years and ≤ 99 years old * Lesion(s) in the infrainguinal arteries: * Lesion above the knee (ATK): Target lesions located in the superficial femoral artery or popliteal arteries (above the tibial plateau) * Lesion below the knee (BTK): Target lesions involve arteries below the tibial plateau * RVD 2-7mm * De novo stenotic, restenotic post POBA, or occlusive lesion(s) * Target lesion must have angiographic evidence of ≥70% stenosis * Lesion length ≥ 3cm * Successful crossing of the target lesion with the guide wire * Successful predilatation, defined as residual stenosis \<50% Rutherford Class 2-5 * Study participant is able to provide consent and has signed and dated the informed consent form
Exclusion criteria
* Life expectancy ≤ 1 year * Study participant is currently participating in another investigational drug or device study that has not reached its primary endpoint yet. * Study participant is pregnant, planning to become pregnant, or father children during the course of the study. * Failure to successfully cross the target lesion with a guide wire (successful crossing means tip of the guide wire distal to the target lesion). * Prior bypass surgery of target vessel * Planned major amputation of the target limb * Thrombus in the target vessel * Known allergy to contrast media that cannot be adequately controlled with premedication * Study participant has a single target lesion that involves both ATK and BTK segments
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Freedom from clinically-driven target lesion revascularization (fcd-TLR) within 12 months post-index procedure. | 12-months post-index procedure | The primary clinical performance endpoint is Freedom from clinically-driven target lesion revascularization (fcd-TLR) within 12 months post-index procedure. |
| Freedom from Major Adverse Events (MAE) through 12 months | Through 12 months post-index procedure | The primary safety endpoint is freedom from major adverse events (MAE), defined as a composite of freedom from device- or procedure-related mortality through 30 days, and freedom from major target limb amputation and clinically driven TLR, within 12 months post-index procedure. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Successful delivery, inflation, deflation, and retrieval of the intact study device during index procedure. | During index procedure | Device success is defined as successful delivery, balloon inflation, deflation, and retrieval of the intact study device without burst below rated burst pressure. |
| Restoration of target lesion with ≤30% residual stenosis in final angiogram. | After index procedure | Procedural success is defined as restoration of the target lesion with ≤30% residual stenosis in the final angiogram. |
| Number of deaths from any cause (all-cause mortality) at 1, 6, 12, 24, 36, 48, and 60 months | At scheduled follow-up visits: 1, 6, 12, 24, 36, 48, and 60 months | All-cause mortality is defined as the total number of deaths from any cause among study participants at each scheduled follow-up time point. |
| Primary patency of target lesion (freedom from clinically driven target lesion revascularization [fcd-TLR] and binary restenosis) | At scheduled follow-up visits: 1, 6, 12, and 24 months | Primary patency is defined as a composite of freedom from clinically driven target lesion revascularization (fcd-TLR) and binary restenosis, where restenosis is defined as duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) ≥2.4 or ≥50% stenosis as assessed by an independent DUS core lab. |
| Freedom from Clinically-driven Target Lesion Revascularization (fcd-TLR) | At scheduled follow-up visits: 1, 6, 24, 36, 48, and 60 months | Clinically driven target lesion revascularization (fcd-TLR) is defined as any reintervention performed for ≥50% diameter stenosis (visual estimate) at the target lesion after documentation of recurrent clinical symptoms. |
| Freedom from Clinically-driven Target Vessel Revascularization (TVR) | At scheduled follow-up visits: 1, 6, 12, 24, 36, 48, and 60 months | Clinically driven TLR is defined as any reintervention performed for ≥50% diameter stenosis (visual estimate) at the target lesion after documentation of recurrent clinical symptoms of the patient. |
| Freedom from major adverse events (MAE: device- or procedure-related mortality, major target limb amputation, and clinically driven TLR) | At scheduled follow-up visits: 1, 6, 24, 36, 48, and 60 months | Major adverse events (MAE) are defined as a composite of freedom from device- or procedure-related mortality through 30 days, freedom from major target limb amputation, and freedom from clinically driven target lesion revascularization (TLR). |
| Amputation-free survival (AFS: alive without major amputation) | At scheduled follow-up visits: 1, 6, 12, 24, 36, 48, and 60 months | Amputation-free survival (AFS) is defined as being alive without major amputation. |
| Freedom from Major Target Limb Amputation | At scheduled follow-up visits: 1, 6, 12, 24, 36, 48, and 60 months | Major target limb amputation is defined as any amputation above the ankle in the target limb. |
| Change from baseline in Rutherford classification at 1, 6, 12, and 24 months | At scheduled follow-up visits: 1, 6, 12, and 24 months | Change from baseline in Rutherford classification will be assessed to evaluate the severity of ischemia in the lower extremities among study participants. |
| Change from baseline in EQ-5D quality of life score at 1, 12, and 24 months | At scheduled follow-up visits: 1, 12, and 24 months | Change from baseline in health-related quality of life, as assessed by the EQ-5D questionnaire, will be evaluated among study participants. |
| Change from baseline in Walking Impairment Questionnaire (WIQ) score at 1, 12, and 24 months | At scheduled follow-up visits: 1, 12, and 24 months | Change from baseline in functional limitations, as assessed by the Walking Impairment Questionnaire (WIQ), will be evaluated among study participants with peripheral artery disease (PAD). |
| Change from baseline in ABI at 1, 6, 12, and 24 months | at 1, 6, 12, and 24 months | ABI is defined as Ankle-Brachial Index (ABI) measurement of the limb being treated |
Countries
Belgium
Contacts
CONTACTAnke Van Roost
Outcome results
None listed